OptiBiotix Signs LPLDL Agreement For Europe With Fine Foods

6th Mar 2018 12:58

LONDON (Alliance News) - OptiBiotix Health PLC announced Tuesday a production and commercialisation agreement with Italian firm Fine Foods & Pharmaceuticals NTM SPA.

The deal gives Fine Foods the exclusive right to produce and supply five formulations containing OptiBiotix's LPLDL strain in return for royalty payments.

The five formulations are for glucose control, high blood pressure reduction, the reduction of cholesterol, and two for the reduction of cardiovascular risk. They will be sold in the form of sachets and melt-in-the-mouth sticks throughout Europe.

OptiBiotix Chief Executive Stephen O'Hara said: "We are pleased to announce this exclusive license agreement with Fine Foods for the production and commercialisation of five new proprietary formulations containing OptiBiotix's LPLDL."

"This agreement extends the range of products and presentations containing OptiBiotix's LPLDL and creates an opportunity to access global pharmaceutical markets with an established industry supplier", O'Hara added.

Shares in OptiBiotix were up 1.3% on Tuesday at 60.80 pence each.

---

Related Shares:

OptiBiotix Health